Taro Pharmaceutical Industries Ltd. (TARO) Receives Approval For Hydrocortisone Butyrate Cream USP, 0.1% ANDA; Generic Equivalent To Locoid(R) Cream
10/19/2005 5:09:05 PM
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Aug. 4, 2005--Taro Pharmaceutical Industries Ltd. (Nasdaq: TARO) reported today that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Hydrocortisone Butyrate Cream USP, 0.1% ("hydrocortisone butyrate cream").
Taro's hydrocortisone butyrate cream is bioequivalent to Ferndale Laboratories' Locoid(R) cream. Hydrocortisone butyrate cream is a prescription topical corticosteroid product used in managing inflammatory skin conditions. According to industry sources, U.S. sales of Locoid(R) cream were approximately $8.2 million in 2004. Taro also markets hydrocortisone butyrate ointment and topical solution products.
comments powered by